Loading clinical trials...
Loading clinical trials...
Characterization of Kidney Involvement in COVID-19 Disease: a French Multi-center Prospective Observational Study
Novel coronavirus disease (COVID-19) is a newly discovered contagious disease caused by SARS-CoV-2 virus, primarily manifesting as an acute respiratory illness with pneumonia, but can affect multiple organs such as kidney, heart, digestive tract, blood and nervous system. In previous reports of SARS and MERS-CoV infections, acute kidney injury was described in 5 to 15% of patients and was associated with a high mortality rate (60-90%). Recent reports showed renal abnormalities in COVID-9 infected patients. A recent Chinese study also reported that acute kidney injury was an independent risk factor for mortality. However, the exact mechanism of kidney involvement remains unclear: sepsis-related cytokine storm or direct cellular injury from the virus. Also, kidney involvement has not yet been well characterized: heavy albuminuria, hematuria or interstitial nephropathy alone. A recent study identified viral RNA in kidney tissue and another study succeeded isolating SARS-CoV-2 from the urine sample of an infected patient. These data suggest that the kidney might be a target of this novel coronarivus. The sponsor suggests characterizing kidney involvement in SARS-CoV-2 infection. Study objectives are: * To give an accurate characterization of kidney involvement in COVID-19 * To investigate the physiopathologic mechanism of kidney involvement in SARS-CoV-2 infection * To identify risk factors for kidney involvement in in SARS-CoV-2 infection * To evaluate the impact of kidney involvement in in SARS-CoV-2 infection * To assess the long-term health effect of kidney injury on survivors of in SARS-CoV-2 infection
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Centre hospitalier d'Antibes Juan les pins
Antibes, France
Centre hospitalier de Cannes
Cannes, France
Centre hospitalier de Grasse
Grasse, France
CHU de Nice
Nice, France
Start Date
April 15, 2020
Primary Completion Date
April 19, 2020
Completion Date
April 19, 2020
Last Updated
April 3, 2025
45
ACTUAL participants
Lead Sponsor
Centre Hospitalier Universitaire de Nice
NCT05806645
NCT06721949
NCT07221162
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions